CZM’s eye attractiveness fades
18/06/24 -"Surprisingly, CZM slashed its full-year guidance yesterday. Greater Chinese exposure (marred by VBP roll-out delays and softer start to the summer peak season) and delayed interest rate cuts weighed ..."
Pages
65
Language
English
Published on
18/06/24
You may also be interested by these reports :
06/11/26
In early September 2026, we suggested that the 5 lean years for MedTechs performance had maybe reached an end. Bingo. The following chart confirms ...
06/11/26
S&N reported Q3 26 revenue of $1,551m (+3.4% organic), in line with consensus. Sports Medicine & ENT led (+7.9%), but continued weakness in US Knees ...
05/11/26
Siemens Healthineers’ Q4 profitability declined and was below market expectations. 2027 guidance also fell short of expectations. We will lower our ...
05/11/26
Tecan’s 3Q sales growth accelerated to 6.9% (LC), well above the 3.4% run rate of 1H26, with both segments contributing to the performance. ...